Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608298 | 0.90 | ALDH1A1 (0.59) | NPSR1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL1073543 | 0.88 | LMNA (0.59) | NPSR1LMNAMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL27039883 | 0.88 | NPSR1 (0.54) | NPSR1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL6229003 | 0.87 | NPSR1 (0.49) | NPSR1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL26451988 | 0.86 | NPSR1 (0.49) | NPSR1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL13913113 | 0.86 | NPSR1 (0.55) | NPSR1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL692491 | 0.85 | NPSR1 (0.67) | NPSR1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL12093424 | 0.84 | NPSR1 (0.47) | NPSR1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL19357068 | 0.84 | LMNA (0.49) | NPSR1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL15432439 | 0.83 | NPSR1 (0.46) | NPSR1LMNAMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421904-B1 | PROCATALYST COMPOSITION WITH ADAMANTANE AND METHOD | GRACE W R & CO (US) | 2015-06-24 | — | — | EP | disclosed |
| US-8288304-B2 | Procatalyst composition with adamantane and method | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288304-B2 | Procatalyst composition with adamantane and method | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288304-B2 | Procatalyst composition with adamantane and method | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120122923-A1 | DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES | SANOFI-AVENTIS (FR) | 2012-05-17 | — | — | US | disclosed |
| US-20120122923-A1 | DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES | SANOFI-AVENTIS (FR) | 2012-05-17 | — | — | US | disclosed |
| EP-2421904-A1 | PROCATALYST COMPOSITION WITH ADAMANTANE AND METHOD | Dow Global Technologies LLC (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123775-A1 | PROCATALYST COMPOSITION WITH ADAMANTANE AND METHOD | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273966-A1 | Procatalyst Composition with Adamantane and Method | W. R. GRACE & CO.-CONN. | 2010-10-28 | — | — | US | disclosed |
| US-20100273966-A1 | Procatalyst Composition with Adamantane and Method | W. R. GRACE & CO.-CONN. | 2010-10-28 | — | — | US | disclosed |
| US-20100273966-A1 | Procatalyst Composition with Adamantane and Method | W. R. GRACE & CO.-CONN. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122923-A1 | DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES | DUOX2, DUOX1, CYP11B2 | NPSR1 1237/4885LMNA 2370/4885MEN1 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.